You can expect a variety of topics this week, including: FDA accepts pembrolizumab as singlea agent for treatment of advanded endometrial cancer New biomarker could predict immunotherapy benefit in breast cancer New Hampshire's abortion restrictions Oral contraceptives and risk of cardiac events in women with congenital long-QT syndrome The impact of nutrition on gynecological diseases